MetaVia Inc. MTVA
MetaVia Inc. (Nasdaq: MTVA) is a cardio-renal-metabolic drug developer. Its lead program, vanoglipel (DA-1241), is in Phase 2 for MASH / metabolic disease. Its next catalyst on record is vanoglipel: finalize Phase 2a Clinical Study Report (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: vanoglipel — finalize Phase 2a Clinical Study Report (Q4 2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| vanoglipel (DA-1241) | MASH (Phase 2a completed; end-of-Phase 2 meeting being scheduled) | small molecule | Phase 2 |
| DA-1726 | obesity (GLP-1/glucagon dual agonist), Phase 1 Part 3a/3b | protein/peptide | Phase 1 |
Recent results and decisions
- Jan 5, 2026positive Non-titrated 48 mg cohort showed 9.1% mean weight loss at day 54, 9.8 cm waist reduction (p=0.022), and 23.7% liver stiffness reduction; no treatment-related discontinuations.
By Day 26, patients receiving DA-1726 achieved a statistically significant average weight reduction of 6.1% (14.6 lbs.) (p=0.003)
Filing - Nov 6, 2025positive DA-1726 32 mg cohort in Phase 1 MAD showed mean weight loss of 4.3% (max 6.3%) at day 26 with no treatment-related discontinuations (re-presented in investor deck).
Day 26 shown dose dependent and compelling BWL shown in 8 mg, 16 mg and 32 mg
Filing - Nov 6, 2025met Vanoglipel Phase 2a primary endpoint met with direct hepatic effects and significant HbA1c reductions vs placebo (re-presented in investor deck).
Phase 2a Primary End Point Met and showed direct hepatic effects
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.